X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2062) 2062
Publication (215) 215
Book Review (23) 23
Book Chapter (9) 9
Conference Proceeding (6) 6
Magazine Article (4) 4
Web Resource (3) 3
Book / eBook (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (1512) 1512
nootropic agents - pharmacology (1197) 1197
male (1167) 1167
index medicus (1019) 1019
humans (907) 907
neurosciences (796) 796
rats (723) 723
nootropic agents - therapeutic use (684) 684
pharmacology & pharmacy (601) 601
female (465) 465
mice (444) 444
alzheimer's disease (392) 392
alzheimer disease - drug therapy (388) 388
disease models, animal (380) 380
alzheimers-disease (379) 379
brain - drug effects (345) 345
memory (340) 340
brain (322) 322
rats, wistar (305) 305
dose-response relationship, drug (300) 300
brain - metabolism (295) 295
nootropic agents - administration & dosage (292) 292
maze learning - drug effects (290) 290
hippocampus - drug effects (286) 286
cognition - drug effects (281) 281
memory - drug effects (267) 267
rats, sprague-dawley (256) 256
neurons - drug effects (241) 241
hippocampus - metabolism (216) 216
neurons - metabolism (209) 209
aged (204) 204
clinical neurology (197) 197
psychiatry (195) 195
alzheimer disease - metabolism (186) 186
oxidative stress (181) 181
cognition (180) 180
neurology (180) 180
hippocampus (178) 178
neuroprotective agents - pharmacology (177) 177
dementia (173) 173
cognition disorders - drug therapy (169) 169
analysis (167) 167
memory disorders - drug therapy (160) 160
time factors (156) 156
mice, inbred c57bl (154) 154
middle aged (153) 153
behavior, animal - drug effects (150) 150
nootropic agents - chemistry (149) 149
nootropic agents - pharmacokinetics (146) 146
random allocation (142) 142
adult (140) 140
neurons (135) 135
nootropic agents - adverse effects (135) 135
avoidance learning - drug effects (134) 134
treatment outcome (134) 134
long-term potentiation (133) 133
biochemistry & molecular biology (128) 128
nootropic agents - metabolism (126) 126
aging (124) 124
amyloid beta-peptides - metabolism (121) 121
article (121) 121
acetylcholinesterase - metabolism (120) 120
motor activity - drug effects (120) 120
double-blind (117) 117
double-blind method (116) 116
mice, transgenic (113) 113
donepezil (112) 112
chemistry, medicinal (110) 110
alzheimer disease - pathology (109) 109
neuropsychological tests (109) 109
rat (107) 107
piperidines - pharmacology (103) 103
maze learning - physiology (102) 102
cholinesterase inhibitors - therapeutic use (101) 101
cerebral cortex - drug effects (98) 98
acetylcholine (97) 97
cholinesterase inhibitors - pharmacology (97) 97
cells, cultured (96) 96
neuroprotective agents - therapeutic use (95) 95
oxidative stress - drug effects (95) 95
metabolism (92) 92
brain - pathology (89) 89
in vitro techniques (88) 88
nerve tissue proteins - metabolism (87) 87
rodents (87) 87
acetylcholinesterase (86) 86
alzheimer disease - physiopathology (86) 86
aged, 80 and over (85) 85
cognitive ability (85) 85
neuroprotection (84) 84
brain - physiopathology (83) 83
piperidines - therapeutic use (83) 83
rat-brain (83) 83
spatial memory (83) 83
memory - physiology (82) 82
biomedicine (81) 81
cerebral cortex - metabolism (81) 81
memory disorders - metabolism (81) 81
research (81) 81
alzheimer disease - psychology (80) 80
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1955) 1955
Russian (71) 71
German (9) 9
Chinese (8) 8
Japanese (8) 8
Spanish (8) 8
French (5) 5
Hungarian (5) 5
Italian (3) 3
Czech (1) 1
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical Pharmacology, ISSN 0006-2952, 09/2017, Volume 139, pp. 40 - 55
Many chronic human diseases, including multiple neurodegenerative diseases, are associated with deleterious protein aggregates, also called protein amyloids.... 
Covalent mechanisms | Non-covalent mechanisms | Amyloid inhibitor | Natural products | Inhibition mechanisms | CLINICAL-TRIAL | PROTEIN AGGREGATION | ALZHEIMERS-DISEASE | SOLID DISPERSION | TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE | ALPHA-SYNUCLEIN AGGREGATION | BETA-PEPTIDE AGGREGATION | A-BETA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | AROMATIC-INHIBITOR | Amyloidosis - prevention & control | Drugs, Investigational - pharmacology | Antioxidants - chemistry | Nootropic Agents - metabolism | Antioxidants - metabolism | Healthy Diet | Humans | Polyphenols - pharmacology | Drugs, Investigational - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Biological Products - pharmacology | Flavonoids - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Polyphenols - metabolism | Amyloidogenic Proteins - antagonists & inhibitors | Drugs, Investigational - chemistry | Protein Aggregation, Pathological - prevention & control | Amyloidosis - diet therapy | Drug Design | Flavonoids - pharmacology | Protein Aggregation, Pathological - diet therapy | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Chelating Agents - therapeutic use | Biological Products - therapeutic use | Chelating Agents - chemistry | Nootropic Agents - therapeutic use | Amyloidosis - drug therapy | Antioxidants - pharmacology | Chelating Agents - pharmacology | Nootropic Agents - chemistry | Drug Discovery | Protein Aggregation, Pathological - drug therapy | Amyloidogenic Proteins - metabolism | Antioxidants - therapeutic use | Biological Products - chemistry | Animals | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Flavonoids - metabolism | Polyphenols - chemistry | Biological Products - metabolism | Polyphenols - therapeutic use | Chelating Agents - metabolism | Dietary Supplements | Flavonoids - chemistry | Amyloidosis - metabolism | Nootropic Agents - pharmacology | Medicine, Experimental | Medical research | Nervous system diseases | Glycoproteins | Drug discovery | Index Medicus
Journal Article
The Journal of Nutritional Biochemistry, ISSN 0955-2863, 09/2017, Volume 47, pp. 1 - 20
Self-assembly of amyloid beta peptide (Aβ) into the neurotoxic oligomers followed by fibrillar aggregates is a defining characteristic of Alzheimer's disease... 
Amyloid beta | Phytochemicals | Biophenols | Alzheimer's disease | Neurodegenerative disorders | ANTIOXIDANT DEFENSE SYSTEM | BIOCHEMISTRY & MOLECULAR BIOLOGY | GINKGO-BILOBA EXTRACT | MILD COGNITIVE IMPAIRMENT | ROSMARINUS-OFFICINALIS L | NUTRITION & DIETETICS | AMYLOID-BETA-PEPTIDE | ACETYLCHOLINESTERASE-INHIBITORY-ACTIVITY | PLACEBO-CONTROLLED TRIAL | IONIZATION MASS-SPECTROMETRY | TRANSGENIC ANIMAL-MODELS | GREEN TEA POLYPHENOL | Neuroprotective Agents - therapeutic use | Stilbenes - adverse effects | Phytochemicals - therapeutic use | Oxidative Stress | Stilbenes - therapeutic use | Nootropic Agents - metabolism | Humans | Stilbenes - metabolism | Flavonoids - adverse effects | Flavonoids - therapeutic use | Neuroprotective Agents - metabolism | Phytochemicals - adverse effects | Plant Extracts - metabolism | Alzheimer Disease - prevention & control | Biomedical Research - methods | Neurons - metabolism | Dietary Supplements - adverse effects | Neuroprotective Agents - adverse effects | Phytochemicals - metabolism | Nootropic Agents - therapeutic use | Phenols - metabolism | Nootropic Agents - adverse effects | Antioxidants - therapeutic use | Animals | Phenols - adverse effects | Flavonoids - metabolism | Phenols - therapeutic use | Alzheimer Disease - metabolism | Models, Neurological | Plant Extracts - therapeutic use | Research Design | Plant Extracts - adverse effects | Oligomers | Peptides
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 01/2015, Volume 113, Issue 2, pp. 350 - 365
Common pharmacological treatments of mood disorders aim to modulate serotonergic neurotransmission and enhance serotonin levels in the brain. Brain serotonin... 
Well-being | Serotonin | LumiVida | Tryptophan | Depression | Cognition | Emotion | FEMALE VOLUNTEERS | PLASMA TRYPTOPHAN | COGNITIVE PERFORMANCE | DEPRESSED-PATIENTS | HEALTHY-SUBJECTS | LumiVida (TM) | ALPHA-LACTALBUMIN INCREASES | NEUTRAL AMINO-ACIDS | VULNERABLE SUBJECTS | NUTRITION & DIETETICS | MOOD | Protein Hydrolysates - metabolism | Stress, Psychological - prevention & control | Nootropic Agents - metabolism | Humans | Middle Aged | Reaction Time | Antidepressive Agents - metabolism | Tryptophan - metabolism | Cognitive Dysfunction - prevention & control | Mental Fatigue - metabolism | Sleep Wake Disorders - metabolism | Depression - metabolism | Egg Proteins, Dietary - adverse effects | Psychiatric Status Rating Scales | Mental Fatigue - prevention & control | Tryptophan - blood | Stress, Psychological - metabolism | Egg Proteins, Dietary - therapeutic use | Female | Dietary Supplements - adverse effects | Beverages | Egg Proteins, Dietary - metabolism | Antidepressive Agents - blood | Serotonin Agents - therapeutic use | Protein Hydrolysates - therapeutic use | Double-Blind Method | Stress, Psychological - blood | Cognitive Dysfunction - metabolism | Nootropic Agents - therapeutic use | Cognitive Dysfunction - blood | Nootropic Agents - blood | Nootropic Agents - adverse effects | Protein Hydrolysates - adverse effects | Serotonin Agents - metabolism | Serotonin Agents - adverse effects | Antidepressive Agents - therapeutic use | Mental Fatigue - blood | Depression - prevention & control | Energy Metabolism | Sleep Wake Disorders - blood | Sleep Wake Disorders - prevention & control | Tryptophan - adverse effects | Aged | Serotonin Agents - blood | Antidepressive Agents - adverse effects | Tryptophan - therapeutic use | Cohort Studies | Depression - blood | Amino acids | Emotional disorders | Cognition & reasoning | Dietary supplements
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 06/2007, Volume 321, Issue 3, pp. 1032 - 1045
Journal Article
Annual Review of Nutrition, ISSN 0199-9885, 7/2016, Volume 36, Issue 1, pp. 211 - 239
Moderately elevated plasma total homocysteine (tHcy) is a strong modifiable risk factor for vascular dementia and Alzheimer's disease. Prospectively, elevated... 
clinical trial | dementia | folate | cobalamin (vitamin B12) | cognition | Alzheimer's disease | PLASMA TOTAL HOMOCYSTEINE | BRAIN ATROPHY | ALZHEIMERS-DISEASE | FATTY-ACID-METABOLISM | RANDOMIZED CONTROLLED-TRIAL | NUTRITION & DIETETICS | SMALL-VESSEL DISEASE | MEDIAL TEMPORAL-LOBE | WHITE-MATTER HYPERINTENSITIES | PLACEBO-CONTROLLED TRIAL | TRANSIENT CEREBRAL-ISCHEMIA | Hyperhomocysteinemia - epidemiology | Folic Acid - therapeutic use | Folic Acid - adverse effects | Neurodegenerative Diseases - etiology | Nootropic Agents - metabolism | Humans | Neurodegenerative Diseases - prevention & control | Hyperhomocysteinemia - metabolism | Vitamin B 12 - adverse effects | Homocysteine - metabolism | Vitamin B 12 - therapeutic use | Cognitive Dysfunction - prevention & control | Hyperhomocysteinemia - physiopathology | Cognition Disorders - prevention & control | Cognition Disorders - etiology | Cognitive Dysfunction - epidemiology | Aging | Nutritional Status | Dietary Supplements - adverse effects | Vitamin B 6 - metabolism | Risk Factors | Homocysteine - blood | Nootropic Agents - therapeutic use | Cerebrovascular Circulation | Cognitive Dysfunction - etiology | Evidence-Based Medicine | Nootropic Agents - adverse effects | Animals | Neurodegenerative Diseases - physiopathology | Vitamin B 6 - adverse effects | Vitamin B 6 - therapeutic use | Biomarkers | Folic Acid - metabolism | Hyperhomocysteinemia - diet therapy | Cognition Disorders - epidemiology | Neurodegenerative Diseases - epidemiology | Vitamin B 12 - metabolism | Practice Guidelines as Topic | Physiological aspects | Homocysteine | Health aspects | Dementia
Journal Article